Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
Metrics to compare | AVCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.6x | −5.4x | −0.5x | |
PEG Ratio | 0.12 | −0.12 | 0.00 | |
Price/Book | 2,423.8x | 2.7x | 2.6x | |
Price / LTM Sales | 3,088.7x | 9.2x | 3.2x | |
Upside (Analyst Target) | 11.0% | 138.7% | 44.2% | |
Fair Value Upside | Unlock | −2.5% | 5.5% | Unlock |